Prot# 20062040//NU0714: A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date6/12/09 → 6/12/18

Funding

  • Amgen, Inc. (20062040//NU0714)